SDZ ABL 364
Alternative Names: ABL 364Latest Information Update: 09 Aug 2002
At a glance
- Originator Novartis; Sandoz
- Class Monoclonal antibodies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 23 Feb 1995 Discontinued-II for Cancer in Switzerland (Unknown route)
- 23 Feb 1995 Preclinical development for Cancer in USA (Unknown route)